Abstract

Errors in mitosis can provide a source of the genomic instability that is typically associated with tumorigenesis. Many mitotic regulators are aberrantly expressed in tumour cells. These proteins could therefore make useful therapeutic targets. The kinases Aurora-A, -B and -C represent a family of such targets and several small-molecule inhibitors have been shown to block their function. Not only have these inhibitors advanced our understanding of mitosis, but, importantly, their in vivo antitumour activity has recently been reported. What have these studies taught us about the therapeutic potential of inhibiting this family of kinases?

Author affiliations

1. Cancer and Infection Research Area, AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Cheshire, SK10 4TG, UK
2. Faculty of Life Sciences, University of Manchester, M13 9PT, UK.

Correspondence to: Nicholas Keen¹ Email: Nick.Keen@astrazeneca.com

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.